Epcoritamab for newly diagnosed marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immunotherapy drug, epcoritamab, for people who have been recently diagnosed with marginal zone lymphoma (MZL) and haven't had treatment yet. The goal is to see if the drug can shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with marginal zone lymphoma (MZL).
- You have not received any previous treatment for your lymphoma (unless it was only localized therapy like radiation or surgery).
- You have at least one lymphoma tumor that can be measured on a scan, or skin or other lesions of a certain size.
- You have symptoms or other signs that mean treatment should start now, like large lymph nodes, fever, night sweats, or weight loss.
- Your blood counts and liver and kidney function meet certain minimum levels.
- You are willing to avoid pregnancy during the trial and for at least 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.